Pharmaceuticals, Biotechnology and Life Sciences
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Teva and Takeda are forming a new joint venture to operate in Japan
A publication on Clever-1 function related to Faron Pharmaceuticals’ novel cancer immunotherapy antibody Clevegen, was published in journal of the American Association of Immunology.
“Ours will be the last generation to see the horror of children paralyzed or killed by polio. I am sure,” said Pr Jacob John, Former Christian Medical College, Vellore, Tamil Nadu, India.
“Maybe we will remember 2015 as the year we took the final step to eradicate this disease forever.”
By Pamela Barbaglia, Olivia Oran and Arno Schuetze LONDON/NEW YORK/FRANKFURT (Reuters) – Investment bank Lazard is working with Sanofi’s management…
Two-decade Pfizer mission pays off for Gueggenheim’s deal king
Impax Laboratories has been granted by the European Commission (EC) authorization to market its Numient oral capsule formulation for the symptomatic treatment of adult patients with Parkinson’s disease.